Potential of ribozymes against deoxycytidine kinase to confer drug resistance to cytosine nucleoside analogs

Biochemical and Biophysical Research Communications

Volumn 278, Issue 3, 2000, Pages 569-575

  Beauséjour, Christian M ^a   Tremblay, Guy ^b   Momparler, Richard L ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cytosine arabinoside; Deoxycytidine kinase; Drug resistance; Gene transfer; Ribozyme

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYTARABINE; CYTOSINE DERIVATIVE; DEOXYCYTIDINE KINASE; GEMCITABINE; PYRIMIDINE NUCLEOTIDE; RIBOZYME; RNA;

ANIMAL CELL; ARTICLE; BLOOD TOXICITY; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE THERAPY; HEMATOPOIETIC STEM CELL; HUMAN; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SIDE EFFECT;

ANIMALIA; MURINAE;

EID: 0034736105     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.3865     Document Type: Article

References (37)

1. Transport and metabolism of deoxycytidine and 1-beta-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis
2. Transfection of wild-type deoxycytidine kinase (dck) cDNA into an AraC- and DAC-resistant rat leukemic cell line of clonal origin fully restores drug sensitivity
3. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine
4. Improved prospects for long-term survival in adults with acute myelogenous leukemia
5. Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine)
6. Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors
7. Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer
8. Chemoprotection against cytosine nucleoside analogs using the human cytidine deaminase gene
9. 'Turning the tables' - Making normal marrow resistant to chemotherapy
10. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1
11. Retroviral transduction of human CD34+ umbilical cord blood progenitor cells with a mutated dihydrofolate reductase cDNA
12. O6-Benzylguanine-resistant mutant MGMT genes improve hematopoietic cell tolerance to alkylating agent
13. Coexpression of cytidine deaminase and mutant dihydrofolate reductase by a bicistronic retroviral vector confers resistance to cytosine arabinoside and methotrexate
14. Retroviral transfer and long-term expression of human cytidine deaminase cDNA in hematopoietic cells following transplantation in mice
15. Studies of the enzymatic deamination of cytosine arabinoside I. Enzyme distribution and species specificity
16. Cytidine deaminase and the development of resistance to arabinosyl cytosine
17. Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells
18. In vivo selection of retrovirally transduced hematopoietic stem cells
19. Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection
20. In vitro leukemia cell models of Ara-C resistance
21. Specificity of ribozyme designed for mutated DHFR mRNA
22. Tumor-specific expression of anti-mdr1 ribozyme selectively restores chemosensitivity in multidrug-resistant colon-adenocarcinoma cells
23. Anti-K-ras ribozyme induces growth inhibition and increased chemosensitivity in human colon cancer cells
24. Retrovirus-mediated transfer of anti-MDR1 ribozymes fully restores chemosensitivity of P-glycoprotein-expressing human lymphoma cells
25. On finding all suboptimal foldings of an RNA molecule
26. Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2'-deoxycytidine against human leukemic cells of different phenotype
27. The structure, function and application of the hammerhead ribozyme
28. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma
29. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer
30. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients
31. Cell cycle regulation of deoxycytidine kinase. Evidence for post-transcriptional control
32. Generality of the NUX rule: Kinetic analysis of the results of systematic mutations in the trinucleotide at the cleavage site of hammerhead ribozymes
33. A human beta-actin expression vector system directs high-level accumulation of antisense transcripts
34. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression
35. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells
36. Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter
37. Construction of a tRNA-embedded-ribozyme trimming plasmid